Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Hemophilia Treatment Market Outlook (2022 to 2032)

The global hemophilia treatment market size was estimated to be worth around US$ 11.1 Billion in 2021. However, with a rapidly increasing hemophilia patient pool worldwide and advancements in hemophilia treatment approaches, the overall demand for hemophilia treatment is projected to rise at 4.8% CAGR during the forecast period, surpassing a valuation of US$ 17.92 Billion by the end of 2032.

Attribute Details
Hemophilia Treatment Market Size (2021) US$ 11.1 Billion
Hemophilia Treatment Market Projected Size (2032) US$ 17.92 Billion
Hemophilia Treatment Market Size (2026) US$ 14.2 Billion
Hemophilia Treatment Market Value CAGR (2022 to 2032) 4.8%
Top Players Biotest AG, Pfizer, CSL Behring, Biogen, Kedrion, Ferring B.V, Genentech, Novo Nordisk, and Octapharma

Hemophilia is an inherited genetic disorder that impairs the body's ability to make blood clots. It occurs when there is any mutation or change in one of the genes that provide instructions for making the clotting factor proteins needed to form a blood clot. As a result, people with this condition (hemophilia) suffer from excessive bleeding after any injury or damage.

As hemophilia is a genetic disorder, there is currently no permanent cure for this medical condition. However, people use various hemophilia treatment therapies to replace the missing factor proteins needed for initiating blood clotting. The adoption of hemophilia treatments like replacement therapy and gene therapy significantly improves the life quality of patients.

Thus, the rising incidence of hemophilia and the increasing need for improving the quality of patient's life will continue to push the demand for hemophilia treatment during the forecast period.

Consequently, the expansion of hemostats for the wound close market and advancements in pharmaceutical drug delivery are likely to assist the hemophilia treatment market growth during the upcoming period.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2015 to 2021 Global Hemophilia Treatment Market Outlook Compared To 2022 to 2032 Forecast

As per FMI, the global hemophilia treatment market is projected to expand at a moderate CAGR of 4.8% during the forecast period from 2022 to 2032. Growth in the market is attributed to the rising prevalence of hemophilia worldwide, advancements in hemophilia treatment therapies, a rise in the rate of diagnostic screening, and increasing government investments and initiatives to reduce the burden of hemophilia.

Hemophilia treatment consists of a wide range of therapies or medications used to improve blood clotting. These therapies work by mimicking the activities of missing or inadequate factor proteins needed for blood clotting.

Over the years, demand for hemophilia treatments such as replacement therapy has risen at a substantial pace on account of their highly effective nature, and the trend is expected to continue during the forecast period. During replacement therapy, concentrates of clotting factor VII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly injected into a vein, where they replace the missing proteins.

The rapidly increasing number of patients suffering from hemophilia is a major factor driving the growth in the hemophilia treatment market. According to the World Federation of Hemophilia (WFH), there were around 393000 people with blood disorders identified and reported globally in 2020. Out of this, 241535 suffered from hemophilia A or B and type unknown. This rise in cases will eventually boost the growth of the hemophilia treatment market during the forecast period.

Similarly, advancements in the rare disease gene therapy market coupled with increasing research and development activities will favor the growth of the hemophilia treatment market.

The latest hemophilia treatment drug industry analysis indicates that a reduction in hemophilia treatment costs and escalating government initiatives to increase diagnostic screening of hemophilia as well as to educate people about hemophilia and its treatments will help hemophilia drug companies increase sales.

Leading hemophilia treatment companies are continuously innovating to expand their customer base and stay relevant in the market. For instance, in 2020 TAKEDA Pharmaceutical Company enabled hemophilia personalized care by launching MYPKFIT SOFTWARE for ADYNOVATE, the first and only FDA-approved pharmacokinetic dosing software and patient app available for ADYNOVATE patients of 12 and older.

What Factors are Limiting the Growth of the Hemophilia Treatment Market?

Some of the major factors restraining the growth of the hemophilia treatment market are the high hemophilia treatment cost, low diagnostic screening rates across low economies, and lack of awareness among people regarding hemophilia and its treatments in some regions

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise Insights

What is the Demand Outlook for the USA Hemophilia Treatment Market?

Rising Hemophilia Patient Pool Driving Market Growth in the USA

As per FMI, the USA accounts for the largest share of the global hemophilia treatment market in 2022 and is expected to grow at a considerable pace during the forecast period.

Growth in the market is driven by the increased number of hemophilic patients, availability of new-gen technology like hemophilia gene therapy, rising diagnostic screening, presence of leading market players, the surge in new drug launches and approvals, and increasing investments in research and development.

According to the National Hemophilia Foundation, there are around 30000 to 33000 people living with hemophilia in the United States and this number is likely to continue rising during the forthcoming period, thereby creating growth prospects within the USA hemophilia treatment market.

Similarly, rising demand for recombinant and plasma-derived products, the growing popularity of gene therapy, and increasing hemophilia research will expand the hemophilia treatment market size in the USA

What Makes China an Attractive Market for Hemophilia Treatments?

Increase in Gene Therapy Research and Favorable Government Support Augmenting Market Growth in China

With a rapidly growing population, increasing prevalence of hemophilia, presence of lax government regulations, and favorable government initiatives, the hemophilia treatment market in China is poised to expand at a rapid pace during the forecast period.

Similarly, advancements in genetic research, new product launches and approvals, growing health awareness among people, and a surge in diagnostic screening are expected to push the demand for hemophilia treatment in China.

For instance, in August 2021 Belief Biomed's Gene Therapy for Hemophilia B (BBM-H901) received China’s National Medical Products Administration (NMPA) IND approval and the company successfully completed dosing of the first subject in the registrational gene therapy clinical trial for hemophilia B in 2022.

Country-wise Insights

Which Disease Segment Holds the Maximum Growth Potential?

Rising Prevalence of Hemophilia a Creating Maximum Growth Prospects

Based on disease, the global market has been segmented into hemophilia A and hemophilia B. Among these, the hemophilia A segment dominated the global hemophilia treatment market in 2021 and is expected to grow at a relatively higher CAGR during the forecast period. The growth of the segment is attributed to the rising prevalence of hemophilia A worldwide.

Hemophilia A, also called classic hemophilia, is the most common type of hemophilia caused by a deficiency of factor VIII (one of the proteins that helps blood to form clots). The rise in the diagnostic rate of hemophilia A along with growing awareness among people about its (hemophilia A) treatments will continue to favor the segment growth during the forecast period.

Which Patient Segment Leads the Hemophilia Treatment Market Growth?

Adults Segment to Contribute Most to the Growth of the Hemophilia Treatment Market

Be patient, the global hemophilia treatment market is segmented into pediatric and adult. Among these, the adult segment is expected to hold the largest share of the hemophilia treatment market during the forecast period, owing to the increasing cases of hemophilia among the adult population and higher detection rates in adults.

Which is the Most Opted Treatment in the Hemophilia Treatment Market?

Demand for prophylaxis To Remain High Throughout the Forecast Period

In terms of treatment, the global hemophilia treatment market is segmented into prophylaxis and on-demand treatment. As per FMI’s latest hemophilia treatment market forecast, the prophylaxis segment is expected to dominate the global hemophilia treatment market during the assessment period.

Prophylaxis treatment has become the standard of care for better treatment in adult patients with hemophilia. People suffering from hemophilia are increasingly opting for prophylaxis treatment to prevent hemophilia/bleeding. As per CDC, prophylaxis decreases the risk of intracranial bleeding by 50% for people with hemophilia.

Which is the Biggest Drug Class Segment in the Hemophilia Treatment Market?

Sales of Vasopressin to Rise at a Considerable Pace in the Market

According to Future Market Insights, the vasopressin segment leads the hemophilia treatment market and it is likely to hold a large portion of the market share by 2032. Growth of the segment is attributed to increasing usage of vasopressin for preventing bleeding of joints & muscles, nose, and mouth as well as improving the survival chances of critically ill patients.

Which is the Preferred Route of Administration?

Injectable Remains Preferred Route of Administration

As per FMI, the injectable segment will continue to dominate the global hemophilia treatment market, owing to the rising preference for administering hemophilia treatment drugs through injectable mode, on account of its user-friendly and fast-acting nature.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Competitive Landscape

The global hemophilia treatment market is highly dynamic in nature with leading hemophilia treatment companies vigorously investing in research and development for introducing novel therapies. Besides this, they have adopted growth strategies such as partnerships, mergers, acquisitions, new product launches and approvals, collaborations, etc. to gain a competitive edge in the global hemophilia treatment market.

For instance:

  • In 2020, Novo Nordisk announced the launch of ESPEROCT®, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A.
  • In April 2020, the USA Food and Drug Administration approved Sevenfact for the treatment of adults suffering from hemophilia A and B.
  • In 2022, Takeda Pharmaceutical Company Limited launched Adynovate, an extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A patients in India.

Hemophilia Treatment Market-Scope of The Report

FMI’s latest report on the hemophilia treatment market provides a detailed analysis of key growth-shaping factors like drivers, restraints, and emerging opportunities. It examines current hemophilia treatment drugs industry trends and highlights their impact on the overall demand for hemophilia treatment.

The report analyzes various hemophilia treatment market segments and regional pockets with the aim of providing a deeper understanding of leading segments. It illustrates how escalation in novel drug development and approvals will increase hemophilia market share during the forthcoming years.

FMI also attempts to provide answers to queries like how will the rise in hemophilia cases influence hemophilia treatment sales. Why is North America a pivotal hemophilia treatment market And Which factors are pushing the demand for hemophilia treatments across the Asia Pacific Detailed information on this is compiled in the global hemophilia treatment market report, which is interspersed with relevant statistics and graphs.

The Hemophilia Treatment Market analysis includes:

  • A 10-year realistic hemophilia treatment sales forecast slicing across several verticals
  • Comprehensive information on demand forecasting and sales prospects across 25 countries
  • Insights into the latest hemophilia treatment market trends
  • Data about leading segments and regional pockets along with their respective shares and growth forecast
  • Market dynamics including drivers, restraints, and emerging opportunities
  • Top hemophilia drug companies and their growth strategies
  • Information about the impact of expanding the drug discovery services market on the overall demand for hemophilia treatments
  • Recent developments in the hemophilia treatment market
  • The winning imperatives in the hemophilia treatment market
Attribute Details
Forecast Period 2022 to 2032
Historic Data Available for 2015 to 2021
Market Analysis USD Million for Value
Report Coverage Market forecast, company share analysis, competition intelligence, Drivers, Restraints, Opportunities and Threats analysis, market dynamics and challenges, and strategic growth initiatives
Key Segments Covered
  • Disease
  • Patient
  • Treatment
  • Therapy
  • Drug Class
  • Route of Administration
  • Region
Key regions covered
  • North America USA
    • Canada
    • Rest of North America
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Western Europe
    • Germany
    • United Kingdom
    • France
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Spain
    • Rest of Eastern Europe
  • South Asia Pacific
    • China
    • India
    • Japan
    • Malaysia
    • Thailand
    • Indonesia
    • South Korea
    • Rest of South Asia & Pacific
  • Middle East & Africa
    • GCC Countries
    • Turkey
    • Israel
    • Rest of the Middle East and Africa(MEA)
  • Rest of the World
    • Oceania
    • Africa
    • South America
Therapy
  • Factor Replacement Therapy
  • Non-factor Replacement Therapy
Key companies profiled Biotest AG, Pfizer, CSL Behring, Biogen, Kedrion, Ferring B.V, Genentech, Novo Nordisk, and Octapharma.
Customization & pricing Available upon request

Key Segments

By Disease:

  • Hemophilia A
  • Hemophilia B

By Patient:

  • Pediatric
  • Adult

By Treatment:

  • Prophylaxis
  • On-Demand

By Therapy:

  • Factor Replacement Therapy
  • Non-factor Replacement Therapy

By Drug Class:

  • Vasopressin
  • Coagulation Factor

By Route of Administration:

  • Injectable
  • Nasal Spray

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa

Frequently Asked Questions

How much was the global hemophilia treatment market worth in 2021?

The global hemophilia treatment market was valued at US$ 11.1 Billion in 2021.

What is the growth outlook for the hemophilia treatment market?

As per FMI, the hemophilia treatment market is expected to grow at a steady CAGR of 4.8% during the projected period.

Which region dominates the global hemophilia treatment market?

North America will continue to lead the global hemophilia treatment market.

Who are the leading players in the hemophilia treatment market?

Biogen, CSL Behring Biotest AG, CSL Behring, Ferring B.V, Genentech, Kedrion, Novo Nordisk, Pfizer, and Octapharma are some of the prominent players operating in the hemophilia treatment market.

Table of Content

1. Executive Summary | Hemophilia Treatment Market

    1.1. Global Market Outlook

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. FMI Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy 

    2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

    3.1. Risk Assessment 

        3.1.1. COVID-19 Crisis and Impact on Demand

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis 

        3.1.3. Impact on Market Value (US$ Million)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background

    4.1.   By Country, US$ Million

    4.2. Market Opportunity Assessment (US$ Million)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast 

        4.3.1. Demand in Optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario 

    4.4. Investment Feasibility Analysis

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

    4.5. Forecast Factors - Relevance & Imp 

        4.5.1. Top Companies Historical Growth

        4.5.2. Global   Growth

        4.5.3. Adoption Rate, By Country

        4.5.4. Investments in 3D Printing Technology

    4.6. Market Dynamics 

        4.6.1. Market Driving Factors and Impact Assessment

        4.6.2. Prominent Market Challenges and Impact Assessment

        4.6.3. Market Opportunities

        4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

    5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

    5.2. Banking on with Segments High Incremental Opportunity

    5.3. Peer Benchmarking 

6. Global Market Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032

    6.1. Historical Market Analysis, 2015 to 2021

    6.2. Current and Future Market Projections, 2022 to 2032

    6.3. Y-o-Y Growth Trend Analysis

7. Global Market Value Analysis 2015 to 2021 and Forecast, 2022 to 2032

    7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021

    7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Disease

    8.1. Introduction / Key Findings

    8.2. Historical Market Value (US$ Million) and AnalysisBy Disease, 2015 to 2021

    8.3. Current and Future Market Value (US$ Million) and Analysis and ForecastBy Disease, 2022 to 2032

        8.3.1. Hemophilia A

            8.3.1.1. Severe

            8.3.1.2. Moderate

            8.3.1.3. Mild

        8.3.2. Hemophilia B

            8.3.2.1. Severe

            8.3.2.2. Moderate

            8.3.2.3. Mild

    8.4. Market Attractiveness AnalysisBy Disease 

9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product

    9.1. Introduction / Key Findings

    9.2. Historical Market Value (US$ Million) and Analysis By Product, 2015 to 2021

    9.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Product, 2022 to 2032

        9.3.1. Recombinant Factor Concentrates

            9.3.1.1. Factor VIII

            9.3.1.2. Factor IX

        9.3.2. Plasma-derived Factor Concentrates

            9.3.2.1. Factor VIII

            9.3.2.2. Factor IX

        9.3.3. Extended Half-life Products

            9.3.3.1. Factor VIII

            9.3.3.2. Factor IX

        9.3.4. Others

    9.4. Market Attractiveness Analysis By Product 

10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Patient

    10.1. Introduction / Key Findings

    10.2. Historical Market Value (US$ Million) and Analysis By Patient, 2015 to 2021

    10.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Patient, 2022 to 2032

        10.3.1. Pediatric

            10.3.1.1. 0 to 4

            10.3.1.2. 5 to 13

            10.3.1.3. 14 to18

        10.3.2. Adult

            10.3.2.1. 19 to 44

            10.3.2.2. 45+

    10.4. Market Attractiveness Analysis By Patient 

11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Treatment

    11.1. Introduction / Key Findings

    11.2. Historical Market Value (US$ Million) and Analysis By Deployment Mode, 2015 to 2021

    11.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Deployment Mode, 2022 to 2032

        11.3.1. Prophylaxis

        11.3.2. On Demand

    11.4. Market Attractiveness Analysis By Deployment Mode

12. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Therapy

    12.1. Introduction / Key Findings

    12.2. Historical Market Value (US$ Million) and Analysis By Therapy, 2015 to 2021

    12.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Therapy, 2022 to 2032

        12.3.1. Factor Replacement Therapy

        12.3.2. Non-factor Replacement Therapy

    12.4. Market Attractiveness Analysis By Therapy 

13. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Drug Class

    13.1. Introduction / Key Findings

    13.2. Historical Market Value (US$ Million) and Analysis By Drug Class, 2015 to 2021

    13.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Drug Class, 2022 to 2032

        13.3.1. Vasopressin

        13.3.2. Coagulation Factors

    13.4. Market Attractiveness Analysis By Drug Class 

14. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Route of Administration

    14.1. Introduction / Key Findings

    14.2. Historical Market Value (US$ Million) and Analysis By Route of Administration, 2015 to 2021

    14.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Route of Administration, 2022 to 2032

        14.3.1. Injectable

        14.3.2. Nasal Spray

    14.4. Market Attractiveness Analysis By Route of Administration 

15. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region

    15.1. Introduction

    15.2. Historical Market Value (US$ Million) and Analysis By Region, 2015 to 2021

    15.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032

        15.3.1. North America

        15.3.2. Latin America

        15.3.3. Europe

        15.3.4. Asia Pacific 

        15.3.5. Middle East and Africa (MEA)

    15.4. Market Attractiveness Analysis By Region

16. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021

    16.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        16.4.1. By Country

            16.4.1.1. USA

            16.4.1.2. Canada

        16.4.2. By Patient 

        16.4.3. By Disease 

        16.4.4. By Product  

        16.4.5. By Treatment 

        16.4.6. By Therapy  

        16.4.7. By Route of Administration  

        16.4.8. By Drug Class 

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Patient 

        16.5.3. By Disease 

        16.5.4. By Product  

        16.5.5. By Treatment 

        16.5.6. By Therapy  

        16.5.7. By Route of Administration  

        16.5.8. By Drug Class 

17. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021

    17.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        17.4.1. By Country

            17.4.1.1. Brazil

            17.4.1.2. Mexico

            17.4.1.3. Rest of Latin America

        17.4.2. By Patient 

        17.4.3. By Disease 

        17.4.4. By Product  

        17.4.5. By Treatment 

        17.4.6. By Therapy  

        17.4.7. By Route of Administration  

        17.4.8. By Drug Class 

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Patient 

        17.5.3. By Disease 

        17.5.4. By Product  

        17.5.5. By Treatment 

        17.5.6. By Therapy  

        17.5.7. By Route of Administration  

        17.5.8. By Drug Class 

18. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032

    18.1. Introduction

    18.2. Pricing Analysis

    18.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021

    18.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        18.4.1. By Country

            18.4.1.1. Germany

            18.4.1.2. France

            18.4.1.3. United Kingdom

            18.4.1.4. Italy

            18.4.1.5. Russia

            18.4.1.6. Rest of Europe

        18.4.2. By Patient 

        18.4.3. By Disease 

        18.4.4. By Product  

        18.4.5. By Treatment 

        18.4.6. By Therapy  

        18.4.7. By Route of Administration  

        18.4.8. By Drug Class 

    18.5. Market Attractiveness Analysis

        18.5.1. By Country

        18.5.2. By Patient 

        18.5.3. By Disease 

        18.5.4. By Product  

        18.5.5. By Treatment 

        18.5.6. By Therapy  

        18.5.7. By Route of Administration  

        18.5.8. By Drug Class 

19. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032

    19.1. Introduction

    19.2. Pricing Analysis

    19.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021

    19.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        19.4.1. By Country

            19.4.1.1. China

            19.4.1.2. Japan

            19.4.1.3. South Korea

            19.4.1.4. Rest of Asia Pacific

        19.4.2. By Patient 

        19.4.3. By Disease 

        19.4.4. By Product  

        19.4.5. By Treatment 

        19.4.6. By Therapy  

        19.4.7. By Route of Administration  

        19.4.8. By Drug Class 

    19.5. Market Attractiveness Analysis

        19.5.1. By Country

        19.5.2. By Patient 

        19.5.3. By Disease 

        19.5.4. By Product  

        19.5.5. By Treatment 

        19.5.6. By Therapy  

        19.5.7. By Route of Administration  

        19.5.8. By Drug Class 

20. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032

    20.1. Introduction

    20.2. Pricing Analysis

    20.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021

    20.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

        20.4.1. By Country

            20.4.1.1. GCC Countries

            20.4.1.2. South Africa

            20.4.1.3. Turkey

            20.4.1.4. Rest of Middle East and Africa

        20.4.2. By Patient 

        20.4.3. By Disease 

        20.4.4. By Product  

        20.4.5. By Treatment 

        20.4.6. By Therapy  

        20.4.7. By Route of Administration  

        20.4.8. By Drug Class 

    20.5. Market Attractiveness Analysis

        20.5.1. By Country

        20.5.2. By Patient 

        20.5.3. By Disease 

        20.5.4. By Product  

        20.5.5. By Treatment 

        20.5.6. By Therapy  

        20.5.7. By Route of Administration  

        20.5.8. By Drug Class 

21. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2032

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. USA Market Analysis

        21.2.1. Value Proportion Analysis by Market Taxonomy

        21.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.2.2.1. By Patient 

            21.2.2.2. By Disease 

            21.2.2.3. By Product  

            21.2.2.4. By Treatment 

            21.2.2.5. By Therapy  

            21.2.2.6. By Route of Administration  

            21.2.2.7. By Drug Class 

    21.3. Canada Market Analysis

        21.3.1. Value Proportion Analysis by Market Taxonomy

        21.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.3.2.1. By Patient 

            21.3.2.2. By Disease 

            21.3.2.3. By Product  

            21.3.2.4. By Treatment 

            21.3.2.5. By Therapy  

            21.3.2.6. By Route of Administration  

            21.3.2.7. By End-User

    21.4. Mexico Market Analysis

        21.4.1. Value Proportion Analysis by Market Taxonomy

        21.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.4.2.1. By Patient 

            21.4.2.2. By Disease 

            21.4.2.3. By Product  

            21.4.2.4. By Treatment 

            21.4.2.5. By Therapy  

            21.4.2.6. By Route of Administration  

            21.4.2.7. By End-User

    21.5. Brazil Market Analysis

        21.5.1. Value Proportion Analysis by Market Taxonomy

        21.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.5.2.1. By Patient 

            21.5.2.2. By Disease 

            21.5.2.3. By Product  

            21.5.2.4. By Treatment 

            21.5.2.5. By Therapy  

            21.5.2.6. By Route of Administration  

            21.5.2.7. By End-User

    21.6. Germany Market Analysis

        21.6.1. Value Proportion Analysis by Market Taxonomy

        21.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.6.2.1. By Patient 

            21.6.2.2. By Disease 

            21.6.2.3. By Product  

            21.6.2.4. By Treatment 

            21.6.2.5. By Therapy  

            21.6.2.6. By Route of Administration  

            21.6.2.7. By End-User

    21.7. France Market Analysis

        21.7.1. Value Proportion Analysis by Market Taxonomy

        21.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.7.2.1. By Patient 

            21.7.2.2. By Disease 

            21.7.2.3. By Product  

            21.7.2.4. By Treatment 

            21.7.2.5. By Therapy  

            21.7.2.6. By Route of Administration  

            21.7.2.7. By End-User

    21.8. Italy Market Analysis

        21.8.1. Value Proportion Analysis by Market Taxonomy

        21.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.8.2.1. By Patient 

            21.8.2.2. By Disease 

            21.8.2.3. By Product  

            21.8.2.4. By Treatment 

            21.8.2.5. By Therapy  

            21.8.2.6. By Route of Administration  

            21.8.2.7. By End-User

    21.9. Russia Market Analysis

        21.9.1. Value Proportion Analysis by Market Taxonomy

        21.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.9.2.1. By Patient 

            21.9.2.2. By Disease 

            21.9.2.3. By Product  

            21.9.2.4. By Treatment 

            21.9.2.5. By Therapy  

            21.9.2.6. By Route of Administration  

            21.9.2.7. By End-User

    21.10. UK Market Analysis

        21.10.1. Value Proportion Analysis by Market Taxonomy

        21.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.10.2.1. By Patient 

            21.10.2.2. By Disease 

            21.10.2.3. By Product  

            21.10.2.4. By Treatment 

            21.10.2.5. By Therapy  

            21.10.2.6. By Route of Administration  

            21.10.2.7. By End-User

    21.11. China Market Analysis

        21.11.1. Value Proportion Analysis by Market Taxonomy

        21.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.11.2.1. By Patient 

            21.11.2.2. By Disease 

            21.11.2.3. By Product  

            21.11.2.4. By Treatment 

            21.11.2.5. By Therapy  

            21.11.2.6. By Route of Administration  

            21.11.2.7. By End-User

    21.12. Japan Market Analysis

        21.12.1. Value Proportion Analysis by Market Taxonomy

        21.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.12.2.1. By Patient 

            21.12.2.2. By Disease 

            21.12.2.3. By Product  

            21.12.2.4. By Treatment 

            21.12.2.5. By Therapy  

            21.12.2.6. By Route of Administration  

            21.12.2.7. By End-User

    21.13. South Korea Market Analysis

        21.13.1. Value Proportion Analysis by Market Taxonomy

        21.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.13.2.1. By Patient 

            21.13.2.2. By Disease 

            21.13.2.3. By Product  

            21.13.2.4. By Treatment 

            21.13.2.5. By Therapy  

            21.13.2.6. By Route of Administration  

            21.13.2.7. By End-User

    21.14. GCC Countries Market Analysis

        21.14.1. Value Proportion Analysis by Market Taxonomy

        21.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.14.2.1. By Patient 

            21.14.2.2. By Disease 

            21.14.2.3. By Product  

            21.14.2.4. By Treatment 

            21.14.2.5. By Therapy  

            21.14.2.6. By Route of Administration  

            21.14.2.7. By End-User

    21.15. South Africa Market Analysis

        21.15.1. Value Proportion Analysis by Market Taxonomy

        21.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.15.2.1. By Patient 

            21.15.2.2. By Disease 

            21.15.2.3. By Product  

            21.15.2.4. By Treatment 

            21.15.2.5. By Therapy  

            21.15.2.6. By Route of Administration  

            21.15.2.7. By End-User

    21.16. Turkey Market Analysis

        21.16.1. Value Proportion Analysis by Market Taxonomy

        21.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032

            21.16.2.1. By Patient 

            21.16.2.2. By Disease 

            21.16.2.3. By Product  

            21.16.2.4. By Treatment 

            21.16.2.5. By Therapy  

            21.16.2.6. By Route of Administration  

            21.16.2.7. By End-User

        21.16.3. Competition Landscape and Player Concentration in the Country

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies 

    22.2. Market Concentration

    22.3. Market Share Analysis of Top Players

    22.4. Market Presence Analysis

        22.4.1. By Regional Footprint of Players

        22.4.2. Product Footprint by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep Dive 

        23.3.1. Bayer Healthcare 

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Sales Footprint

            23.3.1.4. Strategy Overview

        23.3.2. Biogen

            23.3.2.1. Overview

            23.3.2.2. Product Portfolio

            23.3.2.3. Sales Footprint

            23.3.2.4. Strategy Overview

        23.3.3. Biotest AG

            23.3.3.1. Overview

            23.3.3.2. Product Portfolio

            23.3.3.3. Sales Footprint

            23.3.3.4. Strategy Overview

        23.3.4. CSL Behring

            23.3.4.1. Overview

            23.3.4.2. Product Portfolio

            23.3.4.3. Sales Footprint

            23.3.4.4. Strategy Overview

        23.3.5. Ferring B.V

            23.3.5.1. Overview

            23.3.5.2. Product Portfolio

            23.3.5.3. Sales Footprint

            23.3.5.4. Strategy Overview

        23.3.6. Genentech

            23.3.6.1. Overview

            23.3.6.2. Product Portfolio

            23.3.6.3. Sales Footprint

            23.3.6.4. Strategy Overview

        23.3.7. Kedrion

            23.3.7.1. Overview

            23.3.7.2. Product Portfolio

            23.3.7.3. Sales Footprint

            23.3.7.4. Strategy Overview

        23.3.8. Novo Nordisk

            23.3.8.1. Overview

            23.3.8.2. Product Portfolio

            23.3.8.3. Sales Footprint

            23.3.8.4. Strategy Overview

        23.3.9. Octapharma

            23.3.9.1. Overview

            23.3.9.2. Product Portfolio

            23.3.9.3. Sales Footprint

            23.3.9.4. Strategy Overview

        23.3.10. Pfizer

            23.3.10.1. Overview

            23.3.10.2. Product Portfolio

            23.3.10.3. Sales Footprint

            23.3.10.4. Strategy Overview

24. Assumptions and Acronyms Used

25. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million), By Patient, 2015 to 2021

Table 2: Global Market Value (US$ Million), By Patient, 2022 to 2032

Table 3: Global Market Value (US$ Million), By Disease, 2015 to 2021

Table 4: Global Market Value (US$ Million), By Disease, 2022 to 2032

Table 5: Global Market Value (US$ Million), By Product, 2015 to 2021

Table 6: Global Market Value (US$ Million), By Product, 2022 to 2032

Table 7: Global Market Value (US$ Million), By Therapy, 2015 to 2021

Table 8: Global Market Value (US$ Million), By Therapy, 2022 to 2032

Table 9: Global Market Value (US$ Million), By Route of Administration, 2015 to 2021

Table 10: Global Market Value (US$ Million), By Route of Administration, 2022 to 2032

Table 11: Global Market Value (US$ Million), By Deployment Mode, 2015 to 2021

Table 12: Global Market Value (US$ Million), By Deployment Mode, 2022 to 2032

Table 13: Global Market Value (US$ Million), By End-User, 2015 to 2021

Table 14: Global Market Value (US$ Million), By End-User, 2022 to 2032

Table 15: Global Market, By Region, 2015 to 2021

Table 16: Global Market, By Region, 2022 to 2032

Table 17: North America Market Value (US$ Million), By Patient, 2015 to 2021

Table 18: North America Market Value (US$ Million), By Patient, 2022 to 2032

Table 19: North America Market Value (US$ Million), By Disease, 2015 to 2021

Table 20: North America Market Value (US$ Million), By Disease, 2022 to 2032

Table 21: North America Market Value (US$ Million), By Product, 2015 to 2021

Table 22: North America Market Value (US$ Million), By Product, 2022 to 2032

Table 23: North America Market Value (US$ Million), By Therapy, 2015 to 2021

Table 24: North America Market Value (US$ Million), By Therapy, 2022 to 2032

Table 25: North America Market Value (US$ Million), By Route of Administration, 2015 to 2021

Table 26: North America Market Value (US$ Million), By Route of Administration, 2022 to 2032

Table 27: North America Market Value (US$ Million), By Deployment Mode, 2015 to 2021

Table 28: North America Market Value (US$ Million), By Deployment Mode, 2022 to 2032

Table 29: North America Market Value (US$ Million), By End-User, 2015 to 2021

Table 30: North America Market Value (US$ Million), By End-User, 2022 to 2032

Table 31: North America Market, By Country, 2015 to 2021

Table 32: North America Market, By Country, 2022 to 2032

Table 33: Latin America Market Value (US$ Million), By Patient, 2015 to 2021

Table 34: Latin America Market Value (US$ Million), By Patient, 2022 to 2032

Table 35: Latin America Market Value (US$ Million), By Disease, 2015 to 2021

Table 36: Latin America Market Value (US$ Million), By Disease, 2022 to 2032

Table 37: Latin America Market Value (US$ Million), By Product, 2015 to 2021

Table 38: Latin America Market Value (US$ Million), By Product, 2022 to 2032

Table 39: Latin America Market Value (US$ Million), By Therapy, 2015 to 2021

Table 40: Latin America Market Value (US$ Million), By Therapy, 2022 to 2032

Table 41: Latin America Market Value (US$ Million), By Route of Administration, 2015 to 2021

Table 42: Latin America Market Value (US$ Million), By Route of Administration, 2022 to 2032

Table 43: Latin America Market Value (US$ Million), By Deployment Mode, 2015 to 2021

Table 44: Latin America Market Value (US$ Million), By Deployment Mode, 2022 to 2032

Table 45: Latin America Market Value (US$ Million), By End-User2015 to 2021

Table 46: Latin America Market Value (US$ Million), By End-User, 2022 to 2032

Table 47: Latin America Market, By Country, 2015 to 2021

Table 48: Latin America Market, By Country, 2022 to 2032

Table 49: Europe Market Value (US$ Million), By Patient, 2015 to 2021

Table 50: Europe Market Value (US$ Million), By Patient, 2022 to 2032

Table 51: Europe Market Value (US$ Million), By Disease, 2015 to 2021

Table 52: Europe Market Value (US$ Million), By Disease, 2022 to 2032

Table 53: Europe Market Value (US$ Million), By Product, 2015 to 2021

Table 54: Europe Market Value (US$ Million), By Product, 2022 to 2032

Table 55: Europe Market Value (US$ Million), By Therapy, 2015 to 2021

Table 56: Europe Market Value (US$ Million), By Therapy, 2022 to 2032

Table 57: Europe Market Value (US$ Million), By Route of Administration, 2015 to 2021

Table 58: Europe Market Value (US$ Million), By Route of Administration, 2022 to 2032

Table 59: Europe Market Value (US$ Million), By Deployment Mode, 2015 to 2021

Table 60: Europe Market Value (US$ Million), By Deployment Mode, 2022 to 2032

Table 61: Europe Market Value (US$ Million), By End-User, 2015 to 2021

Table 62: Europe Market Value (US$ Million), By End-User, 2022 to 2032

Table 63: Europe Market, By Country, 2015 to 2021

Table 64: Europe Market, By Country, 2022 to 2032

Table 65: Asia Pacific Market Value (US$ Million), By Patient, 2015 to 2021

Table 66: Asia Pacific Market Value (US$ Million), By Patient, 2022 to 2032

Table 67: Asia Pacific Market Value (US$ Million), By Disease, 2015 to 2021

Table 68: Asia Pacific Market Value (US$ Million), By Disease, 2022 to 2032

Table 69: Asia Pacific Market Value (US$ Million), By Product, 2015 to 2021

Table 70: Asia Pacific Market Value (US$ Million), By Product, 2022 to 2032

Table 71: Asia Pacific Market Value (US$ Million), By Therapy, 2015 to 2021

Table 72: Asia Pacific Market Value (US$ Million), By Therapy, 2022 to 2032

Table 73: Asia Pacific Market Value (US$ Million), By Route of Administration, 2015 to 2021

Table 74: Asia Pacific Market Value (US$ Million), By Route of Administration, 2022 to 2032

Table 75: Asia Pacific Market Value (US$ Million), By Deployment Mode, 2015 to 2021

Table 76: Asia Pacific Market Value (US$ Million), By Deployment Mode, 2022 to 2032

Table 77: Asia Pacific Market Value (US$ Million), By End-User, 2015 to 2021

Table 78: Asia Pacific Market Value (US$ Million), By End-User, 2022 to 2032

Table 79: Asia Pacific Market, By Country, 2015 to 2021

Table 80: Asia Pacific Market, By Country, 2022 to 2032

Table 81: MEA Market Value (US$ Million), By Patient, 2015 to 2021

Table 82: MEA Market Value (US$ Million), By Patient, 2022 to 2032

Table 83: MEA Market Value (US$ Million), By Disease, 2015 to 2021

Table 84: MEA Market Value (US$ Million), By Disease, 2022 to 2032

Table 85: MEA Market Value (US$ Million), By Product, 2015 to 2021

Table 86: MEA Market Value (US$ Million), By Product, 2022 to 2032

Table 87: MEA Market Value (US$ Million), By Therapy, 2015 to 2021

Table 88: MEA Market Value (US$ Million), By Therapy, 2022 to 2032

Table 89: MEA Market Value (US$ Million), By Route of Administration, 2015 to 2021

Table 90: MEA Market Value (US$ Million), By Route of Administration, 2022 to 2032

Table 91: MEA Market Value (US$ Million), By Deployment Mode, 2015 to 2021

Table 92: MEA Market Value (US$ Million), By Deployment Mode, 2022 to 2032

Table 93: MEA Market Value (US$ Million), By End-User, 2015 to 2021

Table 94: MEA Market Value (US$ Million), By Drug Class 2022 to 2032

Table 95: MEA Market, By Country, 2015 to 2021

Table 96: MEA Market, By Country, 2022 to 2032
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 2: Global Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million

Figure 3: Global Market Share, By Patient, 2022 & 2032

Figure 4: Global Market Y-o-Y Growth Projections, By Patient – 2022 to 2032

Figure 5: Global Market Attractiveness Index, By Patient – 2022 to 2032

Figure 6: Global Market Share, By Disease, 2022 & 2032

Figure 7: Global Market Y-o-Y Growth Projections, By Disease – 2022 to 2032

Figure 8: Global Market Attractiveness Index, By Disease – 2022 to 2032

Figure 9: Global Market Share, By Therapy, 2022 & 2032

Figure 10: Global Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032

Figure 11: Global Market Attractiveness Index, By Therapy – 2022 to 2032

Figure 12: Global Market Share, By Route of Administration, 2022 & 2032

Figure 13: Global Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032

Figure 14: Global Market Attractiveness Index, By Route of Administration – 2022 to 2032

Figure 15: Global Market Share, By Product, 2022 & 2032

Figure 16: Global Market Y-o-Y Growth Projections, By Product – 2022 to 2032

Figure 17: Global Market Attractiveness Index, By Product – 2022 to 2032

Figure 18: Global Market Share, By Deployment Mode, 2022 & 2032

Figure 19: Global Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032

Figure 20: Global Market Attractiveness Index, By Treatment – 2022 to 2032

Figure 21: Global Market Share, By End-User, 2022 & 2032

Figure 22: Global Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032

Figure 23: Global Market Y-o-Y Growth Projections, By End-User– 2022 to 2032

Figure 24: Global Market Share, By Region, 2022 & 2032

Figure 25: Global Market Y-o-Y Growth Projections, By Region – 2022 to 2032

Figure 26: Global Market Attractiveness Index, By Region – 2022 to 2032

Figure 27: North America Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 28: North America Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million

Figure 29: North America Market Share, By Patient, 2022 & 2032

Figure 30: North America Market Y-o-Y Growth Projections, By Patient – 2022 to 2032

Figure 31: North America Market Attractiveness Index, By Patient – 2022 to 2032

Figure 32: North America Market Share, By Disease, 2022 & 2032

Figure 33: North America Market Y-o-Y Growth Projections, By Disease – 2022 to 2032

Figure 34: North America Market Attractiveness Index, By Disease – 2022 to 2032

Figure 35: North America Market Share, By Therapy, 2022 & 2032

Figure 36: North America Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032

Figure 37: North America Market Attractiveness Index, By Therapy – 2022 to 2032

Figure 38: North America Market Share, By Route of Administration, 2022 & 2032

Figure 39: North America Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032

Figure 40: North America Market Attractiveness Index, By Route of Administration – 2022 to 2032

Figure 41: North America Market Share, By Product, 2022 & 2032

Figure 42: North America Market Y-o-Y Growth Projections, By Product – 2022 to 2032

Figure 43: North America Market Attractiveness Index, By Product – 2022 to 2032

Figure 44: North America Market Share, By Deployment Mode, 2022 & 2032

Figure 45: North America Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032

Figure 46: North America Market Attractiveness Index, By Treatment – 2022 to 2032

Figure 47: North America Market Share, By End-User, 2022 & 2032

Figure 48: North America Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032

Figure 49: North America Market Attractiveness Index, By Drug Class – 2022 to 2032

Figure 50: North America Market Share, By Country, 2022 & 2032

Figure 51: North America Market Y-o-Y Growth Projections, By Country – 2022 to 2032

Figure 52: North America Market Attractiveness Index, By Country – 2022 to 2032

Figure 53: Latin America Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 54: Latin America Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million

Figure 55: Latin America Market Share, By Patient, 2022 & 2032

Figure 56: Latin America Market Y-o-Y Growth Projections, By Patient – 2022 to 2032

Figure 57: Latin America Market Attractiveness Index, By Patient – 2022 to 2032

Figure 58: Latin America Market Share, By Disease, 2022 & 2032

Figure 59: Latin America Market Y-o-Y Growth Projections, By Disease – 2022 to 2032

Figure 60: Latin America Market Attractiveness Index, By Disease – 2022 to 2032

Figure 61: Latin America Market Share, By Therapy, 2022 & 2032

Figure 62: Latin America Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032

Figure 63: Latin America Market Attractiveness Index, By Therapy – 2022 to 2032

Figure 64: Latin America Market Share, By Route of Administration, 2022 & 2032

Figure 65: Latin America Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032

Figure 66: Latin America Market Attractiveness Index, By Route of Administration – 2022 to 2032

Figure 67: Latin America Market Share, By Product, 2022 & 2032

Figure 68: Latin America Market Y-o-Y Growth Projections, By Product – 2022 to 2032

Figure 69: Latin America Market Attractiveness Index, By Product – 2022 to 2032

Figure 70: Latin America Market Share, By Deployment Mode, 2022 & 2032

Figure 71: Latin America Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032

Figure 72: Latin America Market Attractiveness Index, By Treatment – 2022 to 2032

Figure 73: Latin America Market Share, By End-User, 2022 & 2032

Figure 74: Latin America Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032

Figure 75: Latin America Market Attractiveness Index, By Drug Class – 2022 to 2032

Figure 76: Latin America Market Share, By Country, 2022 & 2032

Figure 77: Latin America Market Y-o-Y Growth Projections, By Country – 2022 to 2032

Figure 78: Latin America Market Attractiveness Index, By Country – 2022 to 2032

Figure 79: Europe Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 80: Europe Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million

Figure 81: Europe Market Share, By Patient, 2022 & 2032

Figure 82: Europe Market Y-o-Y Growth Projections, By Patient – 2022 to 2032

Figure 83: Europe Market Attractiveness Index, By Patient – 2022 to 2032

Figure 84: Europe Market Share, By Disease, 2022 & 2032

Figure 85: Europe Market Y-o-Y Growth Projections, By Disease – 2022 to 2032

Figure 86: Europe Market Attractiveness Index, By Disease – 2022 to 2032

Figure 87: Europe Market Share, By Therapy, 2022 & 2032

Figure 88: Europe Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032

Figure 89: Europe Market Attractiveness Index, By Therapy – 2022 to 2032

Figure 90: Europe Market Share, By Route of Administration, 2022 & 2032

Figure 91: Europe Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032

Figure 92: Europe Market Attractiveness Index, By Route of Administration – 2022 to 2032

Figure 93: Europe Market Share, By Product, 2022 & 2032

Figure 94: Europe Market Y-o-Y Growth Projections, By Product – 2022 to 2032

Figure 95: Europe Market Attractiveness Index, By Product – 2022 to 2032

Figure 96: Europe Market Share, By Deployment Mode, 2022 & 2032

Figure 97: Europe Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032

Figure 98: Europe Market Attractiveness Index, By Treatment – 2022 to 2032

Figure 99: Europe Market Share, By End-User, 2022 & 2032

Figure 100: Europe Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032

Figure 101: Europe Market Attractiveness Index, By Drug Class – 2022 to 2032

Figure 102: Europe Market Share, By Country, 2022 & 2032

Figure 103: Europe Market Y-o-Y Growth Projections, By Country – 2022 to 2032

Figure 104: Europe Market Attractiveness Index, By Country – 2022 to 2032

Figure 105: Asia Pacific Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 106: Asia Pacific Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million

Figure 107: Asia Pacific Market Share, By Patient, 2022 & 2032

Figure 108: Asia Pacific Market Y-o-Y Growth Projections, By Patient – 2022 to 2032

Figure 109: Asia Pacific Market Attractiveness Index, By Patient – 2022 to 2032

Figure 110: Asia Pacific Market Share, By Disease, 2022 & 2032

Figure 111: Asia Pacific Market Y-o-Y Growth Projections, By Disease – 2022 to 2032

Figure 112: Asia Pacific Market Attractiveness Index, By Disease – 2022 to 2032

Figure 113: Asia Pacific Market Share, By Therapy, 2022 & 2032

Figure 114: Asia Pacific Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032

Figure 115: Asia Pacific Market Attractiveness Index, By Therapy – 2022 to 2032

Figure 116: Asia Pacific Market Share, By Route of Administration, 2022 & 2032

Figure 117: Asia Pacific Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032

Figure 118: Asia Pacific Market Attractiveness Index, By Route of Administration – 2022 to 2032

Figure 119: Asia Pacific Market Share, By Product, 2022 & 2032

Figure 120: Asia Pacific Market Y-o-Y Growth Projections, By Product – 2022 to 2032

Figure 121: Asia Pacific Market Attractiveness Index, By Product – 2022 to 2032

Figure 122: Asia Pacific Market Share, By Deployment Mode, 2022 & 2032

Figure 123: Asia Pacific Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032

Figure 124: Asia Pacific Market Attractiveness Index, By Treatment – 2022 to 2032

Figure 125: Asia Pacific Market Share, By End-User, 2022 & 2032

Figure 126: Asia Pacific Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032

Figure 127: Asia Pacific Market Attractiveness Index, By Drug Class – 2022 to 2032

Figure 128: Asia Pacific Market Share, By Country, 2022 & 2032

Figure 129: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022 to 2032

Figure 130: Asia Pacific Market Attractiveness Index, By Country – 2022 to 2032

Figure 131: MEA Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 132: MEA Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million

Figure 133: MEA Market Share, By Patient, 2022 & 2032

Figure 134: MEA Market Y-o-Y Growth Projections, By Patient – 2022 to 2032

Figure 135: MEA Market Attractiveness Index, By Patient – 2022 to 2032

Figure 136: MEA Market Share, By Disease, 2022 & 2032

Figure 137: MEA Market Y-o-Y Growth Projections, By Disease – 2022 to 2032

Figure 138: MEA Market Attractiveness Index, By Disease – 2022 to 2032

Figure 139: MEA Market Share, By Therapy, 2022 & 2032

Figure 140: MEA Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032

Figure 141: MEA Market Attractiveness Index, By Therapy – 2022 to 2032

Figure 142: MEA Market Share, By Route of Administration, 2022 & 2032

Figure 143: MEA Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032

Figure 144: MEA Market Attractiveness Index, By Route of Administration – 2022 to 2032

Figure 145: MEA Market Share, By Product, 2022 & 2032

Figure 146: MEA Market Y-o-Y Growth Projections, By Product – 2022 to 2032

Figure 147: MEA Market Attractiveness Index, By Product – 2022 to 2032

Figure 148: MEA Market Share, By Deployment Mode, 2022 & 2032

Figure 149: MEA Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032

Figure 150: MEA Market Attractiveness Index, By Treatment – 2022 to 2032

Figure 151: MEA Market Share, By Drug Class 2022 & 2032

Figure 152: MEA Market Y-o-Y Growth Projections, By End-User– 2022 to 2032

Figure 153: MEA Market Attractiveness Index, By End-User– 2022 to 2032

Figure 154: MEA Market Share, By Country, 2022 & 2032

Figure 155: MEA Market Y-o-Y Growth Projections, By Country – 2022 to 2032

Figure 156: MEA Market Attractiveness Index, By Country – 2022 to 2032

Recommendations

Healthcare

Phototherapy Treatment Market

Published : November 2023

Healthcare

Hypercalcemia Treatment Market

Published : September 2023

Healthcare

Meningitis Treatment Market

Published : November 2022

Healthcare

Epiglottitis Treatment Market

Published : June 2022

Explore Healthcare Insights

View Reports

Hemophilia Treatment Market